EMA expects regulatory evaluation of advanced therapies to gather pace in EU
This article was originally published in Clinica
The European Medicines Agency's Committee for Advanced Therapies says it expects to see more marketing authorisation applications for advanced therapy medicinal products being submitted for review over the next few years in view of the growing R&D pipeline in this sector. In 2013 alone, it expects to receive three to four new marketing applications.
Register for our free email digests: